Treatment of Pulmonary Arterial Hypertension With the Selective Endothelin-A Receptor Antagonist Sitaxsentan
Robyn J. Barst, MD*,*,
David Langleben, MD ,
David Badesch, MD ,
Adaani Frost, MD ,
E. Clinton Lawrence, MD||,
Shelley Shapiro, MD¶,
Robert Naeije, MD#,
Nazzareno Galie, MD** on behalf of the STRIDE-2 Study Group
* Department of Pediatrics, Columbia University Medical Center, New York, New York
Jewish General Hospital, Montreal, Quebec, Canada
University of Colorado, Denver, Colorado
Baylor College of Medicine, Houston, Texas
|| McKelvey Lung Transplantation Center, Emory University, Atlanta, Georgia
¶ University of Southern California, Los Angeles, California
# Erasmus University, Brussels, Belgium
** Institute of Cardiology, University of Bologna, Bologna, Italy
View larger version (13K):
[in a new window]
|
Figure 1 Patient disposition. BID = twice a day; OL = open label; QD = once daily.
|
|
View larger version (12K):
[in a new window]
|
Figure 2 Mean (±SE) change in six-min walk (6MW) distance from baseline to week 18 in the placebo, sitaxsentan 50-mg, sitaxsentan 100-mg, and open label (OL) bosentan groups. *p = 0.03 (95% confidence interval 5.37, 57.44) for comparison between the 100-mg dose of sitaxsentan and placebo, **p = 0.05 for OL bosentan vs. placebo, and p = 0.07 for 50-mg sitaxsentan vs. placebo.
|
|
View larger version (32K):
[in a new window]
|
Figure 3 Change in World Health Organization functional class from baseline to week 18 in the placebo, sitaxsentan 50-mg, sitaxsentan 100-mg, and open label (OL) bosentan groups. *p = 0.04 for comparison between the 100-mg dose of sitaxsentan and placebo; there was no difference for either the sitaxsentan 50-mg group or the OL bosentan group vs. placebo. BL = baseline.
|
|
|
